The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Harbour BioMed and Bristol Myers Squibb Enter into Global Strategic Collaboration Agreement to Develop Multi-Specific Antibodies.
Dec 17, 2025•6 months ago
Contract Type
agreement
CambridgeBiotechnologyTherapeuticsBiopharma
Description
Harbour BioMed has announced a multi-year global strategic collaboration agreement with Bristol Myers Squibb. The agreement focuses on the discovery and development of next-generation multi-specific antibodies, potentially earning Harbour BioMed up to $1.125 billion in total payments.
Company Information
Company
Harbour BioMed
Location
Cambridge, Massachusetts, United States
About
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
CambridgeBiotechnologyTherapeuticsBiopharma